1. Home
  2. MTN vs CRSP Comparison

MTN vs CRSP Comparison

Compare MTN & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Vail Resorts Inc.

MTN

Vail Resorts Inc.

HOLD

Current Price

$136.75

Market Cap

4.9B

ML Signal

HOLD

Logo CRISPR Therapeutics AG

CRSP

CRISPR Therapeutics AG

HOLD

Current Price

$48.70

Market Cap

4.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MTN
CRSP
Founded
1997
2013
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Services-Misc. Amusement & Recreation
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.9B
4.7B
IPO Year
1997
2016

Fundamental Metrics

Financial Performance
Metric
MTN
CRSP
Price
$136.75
$48.70
Analyst Decision
Buy
Buy
Analyst Count
12
20
Target Price
$173.17
$71.95
AVG Volume (30 Days)
826.2K
1.7M
Earning Date
03-09-2026
02-11-2026
Dividend Yield
6.34%
N/A
EPS Growth
17.26
N/A
EPS
7.24
N/A
Revenue
$2,975,101,000.00
$38,337,000.00
Revenue This Year
$1.78
N/A
Revenue Next Year
$3.98
$1,478.13
P/E Ratio
$19.33
N/A
Revenue Growth
3.06
N/A
52 Week Low
$126.16
$30.04
52 Week High
$175.51
$78.48

Technical Indicators

Market Signals
Indicator
MTN
CRSP
Relative Strength Index (RSI) 48.77 41.74
Support Level $135.99 $46.48
Resistance Level $145.89 $50.63
Average True Range (ATR) 4.95 2.56
MACD 0.88 -0.36
Stochastic Oscillator 56.52 28.67

Price Performance

Historical Comparison
MTN
CRSP

About MTN Vail Resorts Inc.

Vail Resorts Inc Bhd is a resorts and casinos company that operates mountain resorts and ski areas. The company has three business segments that include Mountain, Lodging, and Real Estate. The Mountain segment operates numerous ski resort properties that offer a variety of winter and summer activities, such as skiing, snowboarding, snowshoeing, hiking, and mountain biking. The Lodging segment owns and operates hotels and condominiums. The Real Estate segment owns, develops, and leases real estate, typically near its other properties. The company generates the vast majority of its revenue within the United States.

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

Share on Social Networks: